Bio­gen's Q3 rev­enue de­clines 10% as fo­cus shifts to new Alzheimer's and ALS drug can­di­dates

While Bio­gen’s Q3 rev­enue dipped by 10% ver­sus the pri­or year, the com­pa­ny fo­cused its earn­ings call on two bright prospects — re­cent­ly un­veiled pos­i­tive re­sults for lecanemab, its an­ti-amy­loid Alzheimer’s fol­low-up to Aduhelm, and its po­ten­tial ALS drug tofersen.

The FDA has un­til Jan. 6, 2023, to de­cide on lecanemab’s ac­cel­er­at­ed ap­proval, and Bio­gen ex­ecs, who have part­nered with Ei­sai on the new drug with 50-50 prof­it shar­ing, in­di­cat­ed that a full ap­proval sub­mis­sion would soon fol­low in the US, EU and Japan be­fore the end of Q1 2023.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.